Conscious choice of world clinicians in pharmacotherapy of ventricular arrhythmias: from myths to practical recommendations | Ukrainian Medical Journal

The article discusses the most common myths and prejudices about the occurrence of ventricular arrhythmias and the possibility of their correction with antiarrhythmic drugs. The provisions of the current ESC guidelines for the treatment of ventricular arrhythmias and prevention of sudden cardiac death (2022) are presented, some provisions of the American Heart Association (2017) and the Canadian Cardiovascular Society (2020) are commented on, revealing the possibilities of using Ic class of antiarrhythmic drugs in the treatment of idiopathic ventricular tachycardia. The results of randomized controlled trials demonstrating the efficacy and safety of long-term use of flecainide, a Iс class antiarrhythmic drug, are presented.

References

1. Lippi G., Sanchis-Gomar F., Cervellin G. (2021) Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke, 16(2): 217–221. doi: 10.1177/1747493019897870.
2. Samuel M., Elsokkari I., Sapp J.L. (2022) Ventricular Tachycardia Burden and Mortality: Association or Causality? Can. J. Cardiol., 38(4): 454–464.
3. Mallhi T.H., Safdar A., Butt M. et al. (2024) Atypical Complications during the Course of COVID-19: A Comprehensive Review. Medicina (Kaunas), 60(1): 164.
4. Rath B., Doldi F., Willy K. et al. (2024) Ventricular arrhythmia burden in ICD patients during the second wave of the COVID-19 pandemic. Clin. Res. Cardiol., 113(10): 1463–1468. doi: 10.1007/s00392-023-02320-2.
5. Tan Z., Huang S., Mei K. et al. (2022) The Prevalence and Associated Death of Ventricular Arrhythmia and Sudden Cardiac Death in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8: 795750.
6. McCullough P.A., Hulscher N. (2025) Risk stratification for future cardiac arrest after COVID-19 vaccination. World J. Cardiol., 17(2): 103909.
7. Gabet A., Lailler G., Fauchier L. et al. (2024) Epidemiology of major heart rhythm and conduction disorders. Arch. Cardiovasc. Dis., 117(12): 693–704.
8. Martin S.S., Aday A.W., Allen N. et al. (2025) 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 151(8): e41–e660. doi: 10.1161/CIR.0000000000001303.
9. Mamas M.A., Martin G.P., Grygier M. et al. (2024) Indirect impact of the war in Ukraine on primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in Poland. Pol. Arch. Intern. Med., 134(6): 16737.
10. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J., 2022; 43(40): 3997–4126. doi: 10.1093/eurheartj/ehac262.
11. Sirichand S., Killu A.M., Padmanabhan D. et al. (2017) Incidence of Idiopathic Ventricular Arrhythmias: A Population-Based Study. Circ. Arrhythm. Electrophysiol., 10(2): e004662. doi: 10.1161/CIRCEP.116.004662.
12. Tan N.Y., Roger V.L., Killian J. et al. (2022) Ventricular Arrhythmias Among Patients With Advanced Heart Failure: A Population-Based Study. J. Am. Heart Assoc., 11(1): e023377. doi: 10.1161/JAHA.121.023377.
13. Sau A., Kaura A., Ahmed A. et al. (2022) Prognostic Significance of Ventricular Arrhythmias in 13 444 Patients With Acute Coronary Syndrome: A Retrospective Cohort Study Based on Routine Clinical Data (NIHR Health Informatics Collaborative VA-ACS Study). J. Am. Heart Assoc., 11(6): e024260. doi: 10.1161/JAHA.121.024260.
14. Echivard M., Sellal J.M., Ziliox C. et al. (2022) Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study. Eur. Heart J., 45(41): 4428–4442. doi: 10.1093/eurheartj/ehae575.
15. Alenazy B., Tharkar S., Kashour T. et al. (2019) In-hospital ventricular arrhythmia in heart failure patients: 7 year follow-up of the multi-centric HEARTS registry. ESC Heart Fail., 6(6): 1283–1290. doi: 10.1002/ehf2.12525.
16. El Hajjar A.H., El Helou M.C., Bayat A. et al. (2024) Ventricular Tachycardia as a Late Complication of COVID-19 in a Young Patient With No History of Cardiovascular Disease. CJC Open, 6(5): 721–724. doi: 10.1016/j.cjco.2024.01.010.
17. Ogiso S., Arita T., Suzuki S. et al. (2024) Association between ventricular arrhythmia (premature ventricular contractions burden and nonsustained ventricular tachycardia) and cardiovascular events in patients without structural heart disease. J. Arrhythm., 41(1): e13203. doi: 10.1002/joa3.13203.
18. Lawley C.M., Tester M., Sanatani S. et al. (2022) Life-threatening cardiac arrhythmia and sudden death during electronic gaming: An international case series and systematic review. Heart Rhythm., 19(11): 1826–1833.
19. Haugaa K.H., Dan G.A., Iliodromitis K. et al. (2018) Management of patients with ventricular arrhythmias and prevention of sudden cardiac death-translating guidelines into practice: results of the European Heart Rhythm Association survey. Europace, 20(FI2): f249–f253. doi: 10.1093/europace/euy112.
20. Aktaa S., Tzeis S., Gale C. et al. (2023) European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 25(1): 199–210.
21. Könemann H., Ellermann C., Zeppenfeld K. et al. (2023) Management of Ventricular Arrhythmias Worldwide: Comparison of the Latest ESC, AHA/ACC/HRS, and CCS/CHRS Guidelines. JACC Clin. Electrophysiol., 9(5): 715–728.
22. Al-Khatib S.M., Stevenson W.G., Ackerman M. et al. (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm., 15(10): e73–e189.
23. Rillig A., Eckardt L., Borof K. et al. (2024) Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial. Europace, 26(6): euae121. doi: 10.1093/europace/euae121.
24. Kiani S., Sayegh M.N., Ibrahim R. et al. (2023) The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease. JACC Clin. Electrophysiol., 9(7 Pt 2): 1172–1180. doi: 10.1016/j.jacep.2022.12.021.
25. Siponen R., Hartikainen J., Virrankorpi J. et al. (2025) The use of antiarrhythmic drugs for atrial fibrillation in Finland 2007–2018. Scand. Cardiovasc. J., 59(1): 2467735. doi: 10.1080/14017431.2025.2467735.
26. Kojić D., Radunović A., Bukumirić Z. et al. (2023) Idiopathic premature ventricular complexes treatment: Comparison of flecainide, propafenone, and sotalol. Clin. Cardiol., 46(10): 1220–1226. doi: 10.1002/clc.24090.
27. Van Gelder I.C., Rienstra M., Bunting K.V. et al. (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 45(36): 3314–3414.
28. Інструкція до препарату Ліксарит. https://compendium.com.ua/dec/355526/586817.
29. Lavalle C., Trivigno S., Vetta G. et al. (2021) Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives. J. Clin. Med., 10(16): 3696.